Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential

Journal of Pharmaceutical Sciences

Volumn 93, Issue 6, 2004, Pages 1557-1565

  Egito, Lucila C M ^a   Batistuzzo De Medeiros, Silvia R ^a   Medeiros, Maria G ^a   Price, James C ^b   Egito, E Sócrates T ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF GEORGIA   (United States)

^c Rua Praia de Areia Branca   (Brazil)

Author keywords

Absorption spectra; Amphotericin B; Cytotoxicity; Fungizone ; Genotoxicity

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; WATER;

ADULT; AQUEOUS SOLUTION; ARTICLE; CELL CYCLE G2 PHASE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STRUCTURE; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MAMMAL CELL; MITOSIS INDEX; NORMAL HUMAN; PHYSICAL CHEMISTRY; SPECTROPHOTOMETRY;

EID: 2642527135     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20038     Document Type: Article

References (33)

1. Donovick R, Gold W, Pagano JF, Stout HA. 1955-1956. Amphotericin A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Annu 3:579-586.
2. Hartsel S, Bolard J. 1996. Amphotericin B: New life for an old drug. Trends Pharmacol Sci 17:445-449.
3. Asher IM, Schwartzman G, USASRG. 1972. Amphotericin B. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic Press, pp 1-42.
4. Bartner E, Zinnes H, Moe RA, Kulesza JS. 1957-1958. Studies on a new solubilized preparation of amphotericin B. Antibiot Annu 5:53-58.
5. Groll AH, Muller FMC, Piscitelli SC, Walsh TJ. 1998. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 210:264-273.
6. Saxena S, Ghosh PC. 2000. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A-fumigatus infected mice. Pharm Res 17:1236-1242.
7. Burgess JL, Birchall R. 1972. Nephrotoxicity of amphotericin-B, with emphasis on changes in tubular function. Am J Med 53:77-84.
8. Bolard J. 1986. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 864:257-304.
9. Lamy-Freund MT, Ferreira VFN, Faljonialario A, Schreier S. 1993. Effect of aggregation on the kinetics of autoxidation of the polyene antibiotic amphotericin-B. J Pharm Sci 82:162-166.
10. Sokol-Anderson ML, Brajtburg J, Medoff G. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 154:76-83.
11. Bolard J, Legrand P, Heitz F, Cybulska B. 1991. One-sided action of amphotericin-B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30:5707-5715.
12. Hartsel SC, Benz SK, Ayenew W, Bolard J. 1994. Na+, K+ and Cl- selectivity of the permeability pathways induced through sterol-containing membrane vesicles by amphotericin B and other polyene antibiotics. Eur Biophys J 23:125-132.
13. Bolard J, Seigneuret M, Boudet G. 1980. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: Lipid state and cholesterol content dependence. Biochim Biophys Acta 599:280-293.
14. Atkinson AJJ, Benett JE. 1978. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13:271-276.
15. Mitelman F. 1991. Catalog of chromosome aberrations in cancer. 5th ed. New York: Wiley, 1146 pp.
16. Tucker JD, Preston RJ. 1996. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res 365:147-159.
17. Choudhury RC, Ghosh SK, Palo AK. 2000. Cytogenetic toxicity of methotrexate in mouse bone marrow. Environ Toxicol Pharmacol 8:191-196.
18. Suter W, Hartmann A, Poetter F, Sagelsdorff P, Hoffmann P, Martus HJ. 2002. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res 518:181-194.
19. Blasiak J, Gloc E, Wozniak K, Mlynarski W, Stolarska M, Skorski T, Majsterek I. 2002. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact 140:1-18.
20. Fogu G, Congiu AM, Campus PM, Ladu R, Sanna R, Sini MC, Soro G. 2000. Genotoxic effects of cadmium chloride on human amniotic fluid cells cultured in vitro. Ann Chim 90:709-714.
21. Wang TC, Lee ML. 2001. Effect of fetal calf serum on the cadmium clastogenicity. Mutat Res 498:79-87.
22. Aramwit P, Yu BG, Lavasanifar A, Samuel J, Kwon GS. 2000. The effect of serum albumin on the aggregation state and toxicity of amphotericin B. J Pharm Sci 89:1589-1593.
23. Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA. 1960. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 20:613-616.
24. Savage JRK. 1976. Classification and relationships of induced chromosomal structural changes. J Med Genet 13:103-122.
25. Egito EST, Araujo IB, Damasceno B, Price JC. 2002. Amphotericin B/emulsion admixture interactions: An approach concerning the reduction of amphotericin B toxicity. J Pharm Sci 91:2354-2366.
26. Preston RJ, Sebastian JRS, McFee AF. 1987. The in vitro human lymphocyte assay for assessing the clastogenicity of chemical agents. Mutat Res 189:175-183.
27. Lamy-Freund MT, Ferreira VFN, Schreier S. 1985. Mechanism of inactivation of the polyene antibiotic amphotericin-B: Evidence for radical formation in the process of autoxidation. J Antibiot 38:753-757.
28. Jayanthi A, Subramanyam S. 1995. Genotoxicity of the systemic antifungal antibiotic amphotericin B in vitro. Biol Zent bl 114:285-293.
29. Snyder RD, Green JW. 2001. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488:151-169.
30. Egito EST, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet JP. 1996b. In vitro and in vivo evaluation of a new amphotericin B emulsion-based delivery system. J Antimicrob Chemother 38:485-497.
31. Preston RJ, Dean BJ, Galloway S, Holden H, McFee AF, Shelby M. 1987. Mammalian in vivo cytogenetic assays: Analysis of chromosome aberrations in bone-marrow cells. Mutat Res 189:157-165.
32. Kihlman BA, Hansson K, Palitti F, Anderson HC, Hantley ASP. 1982. Potentiation of induced chromatid-type aberrations by hydroxyurea and caffeine in G2. In: Natarajan AT, Altman H, Obe G, editors. Progress in mutation research. Amsterdam: Elsevier, pp 11-24.
33. Pincheira J, Gallo C, Bravo M, Navarrete MH, Lopezsaez JF. 1993. G(2)-repair and aging: Influence of donor age on chromosomal aberrations in human lymphocytes. Mutat Res 295:55-62.